Perrigo (PRGO) is trading up at $14.44 (+1.26%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Perrigo revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.28B | $4.95B | $4.73B | $3.87B | $4.09B | $4.14B | $4.45B | $4.66B | $4.37B | $4.25B |
| Growth (year over year) | +24.9% | −6.3% | −4.3% | −18.2% | +5.6% | +1.2% | +7.6% | +4.6% | −6.1% | −2.8% |
| Gross profit | $2.05B | $1.98B | $1.83B | $1.43B | $1.49B | $1.42B | $1.46B | $1.68B | $1.54B | $1.49B |
| Gross margin | 38.9% | 40.0% | 38.7% | 37.0% | 36.6% | 34.2% | 32.7% | 36.1% | 35.3% | 35.1% |
| Operating income | −$2.00B | $598.2M | $236.5M | $174.7M | $265.2M | $410.4M | $78.9M | $151.9M | $112.9M | −$1.12B |
| Operating margin | −37.9% | 12.1% | 5.0% | 4.5% | 6.5% | 9.9% | 1.8% | 3.3% | 2.6% | −26.4% |
| Net income | −$4.01B | $119.6M | $131.0M | $146.1M | −$162.6M | −$68.9M | −$140.6M | −$12.7M | −$171.8M | −$1.43B |
| Net margin | −76.0% | 2.4% | 2.8% | 3.8% | −4.0% | −1.7% | −3.2% | −0.3% | −3.9% | −33.5% |
| EPS (diluted) | −$28.01 | $0.84 | $0.95 | $1.07 | −$1.19 | −$0.52 | −$1.04 | −$0.09 | −$1.25 | −$10.29 |
| Balance sheet | ||||||||||
| Cash and equivalents | $622.3M | $678.7M | $551.1M | $354.3M | $631.5M | $1.86B | $600.7M | $751.3M | $558.8M | $531.6M |
| Total assets | $13.9B | $11.6B | $11.0B | $11.3B | $11.5B | $10.4B | $11.0B | $10.8B | $9.65B | $8.54B |
| Total liabilities | $7.91B | $5.46B | $5.32B | $5.50B | $5.83B | $5.27B | $6.18B | $6.04B | $5.33B | $5.60B |
| Long-term debt | $5.22B | $3.27B | $3.05B | $3.37B | $3.53B | $2.92B | $4.07B | $3.63B | $3.58B | $3.60B |
| Shareholders' equity | $5.96B | $6.17B | $5.67B | $5.80B | $5.66B | $5.15B | $4.84B | $4.77B | $4.32B | $2.94B |
| Cash flow | ||||||||||
| Operating cash flow | $654.9M | $698.9M | $593.0M | $387.8M | $636.2M | $156.3M | $307.3M | $405.5M | $362.9M | $238.5M |
| Capital expenditure | $106.2M | $88.6M | $102.6M | $137.7M | $170.4M | $152.1M | $96.4M | $101.7M | $118.3M | $93.4M |
| Free cash flow | $548.7M | $610.3M | $490.4M | $250.1M | $465.8M | $4.20M | $210.9M | $303.8M | $244.6M | $145.1M |
| Dividends paid | $83.2M | $91.1M | $104.9M | $112.4M | $123.9M | $129.6M | $142.4M | $149.7M | $152.5M | $159.3M |
| Share buybacks | $0 | $191.5M | $400.0M | $0 | $164.2M | $0 | $0 | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.09B | $1.14B | $1.04B | $1.06B | $1.04B | $1.11B | $969.2M | $1.02B |
| Growth (year over year) | −3.2% | −1.6% | −3.5% | −0.9% | −4.1% | −2.5% | −7.2% | −3.2% |
| Gross profit | $404.4M | $385.9M | $392.3M | $362.9M | $377.1M | $362.2M | $325.5M | $313.9M |
| Gross margin | 37.2% | 33.9% | 37.6% | 34.4% | 36.1% | 32.6% | 33.6% | 30.7% |
| Operating income | $80.4M | $114.2M | $46.9M | $45.4M | $72.6M | −$1.29B | −$372.3M | $23.5M |
| Operating margin | 7.4% | 10.0% | 4.5% | 4.3% | 7.0% | −116.0% | −38.4% | 2.3% |
| Net income | −$21.0M | −$44.4M | −$6.40M | −$8.40M | $7.50M | −$1.42B | −$398.6M | $74.5M |
| Net margin | −1.9% | −3.9% | −0.6% | −0.8% | 0.7% | −127.8% | −41.1% | 7.3% |
| EPS (diluted) | −$0.15 | −$0.32 | −$0.05 | −$0.06 | $0.05 | −$10.23 | −$2.87 | $0.53 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.46B | $558.8M | $409.9M | $454.2M | $432.1M | $531.6M | $357.2M | $399.7M |
| Total assets | $11.2B | $9.65B | $9.76B | $10.1B | $10.1B | $8.54B | $7.98B | $7.61B |
| Total liabilities | $6.64B | $5.33B | $5.40B | $5.62B | $5.64B | $5.60B | $5.48B | $5.09B |
| Long-term debt | $4.31B | $3.58B | $3.59B | $3.62B | $3.61B | $3.60B | $3.62B | $3.28B |
| Shareholders' equity | $4.57B | $4.32B | $4.36B | $4.47B | $4.45B | $2.94B | $2.50B | $2.52B |
| Cash flow | ||||||||
| Operating cash flow | $42.2M | $312.6M | −$64.5M | $75.9M | $51.7M | $175.4M | −$113.6M | $82.6M |
| Capital expenditure | $27.1M | $37.7M | $25.5M | $19.2M | $21.9M | $26.8M | $13.8M | $14.3M |
| Free cash flow | $15.1M | $274.9M | −$90.0M | $56.7M | $29.8M | $148.6M | −$127.4M | $68.3M |
| Dividends paid | $37.6M | $39.6M | $40.6M | $38.9M | $39.9M | $39.9M | $39.9M | $40.2M |
From Perrigo's 10-K, 10-KT and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Perrigo
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters in Grand Rapids, Michigan, within Michigan State University's Grand Rapids Innovation Park.
- Headquarters
- Dublin, Ireland From SEC filings, Oct 2026
Recent News
No recent news mentioning Perrigo in our feed yet.
Other Health Care companies to compare with PRGO
- PNTG Pennant Group Inc
- PRAX Praxis Precision Medicines Inc
- PRCT Procept Biorobotics Corp
- PRFX PRF Technologies
- PRLD Prelude Therapeutics
- PRME Prime Medicine Inc
- PROK ProKidney
- PRTA Prothena PLC